Drug Profile
Enzalutamide - Astellas Pharma/Medivation
Alternative Names: ASP-9785; MDV-3100; XtandiLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
- Developer Alliance for Clinical Trials in Oncology; Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Pfizer; Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago; University of Rochester
- Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Prostate cancer
- Phase II Bladder cancer; Breast cancer; Endometrial cancer; Ovarian cancer; Salivary gland cancer
- Discontinued Liver cancer
Most Recent Events
- 22 Mar 2024 Astellas anticipates additional license applications for enzalutamide in Prostate cancer and other indication with regulatory authorities in 2024 and beyond
- 22 Mar 2024 Astellas Pharma anticipates a decision on EU marketing authorisation for enzalutamide in non-metastatic hormone sensitive Prostate cancer by June 2024
- 22 Mar 2024 CHMP of the EMA adopts a positive opinion recommending approval of enzalutamide as a monotherapy or combination therapy for Prostate cancer (nmHSPC)